Navigation Links
Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
Date:9/25/2008

odysplastic syndrome (MDS). (5,6,7,8,9) In patients with thrombosis of unknown origin, PNH may be an underlying cause. (3,9)

Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk. (3,9)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis. In June 2007, the European Commission (EC) also approved the use of Soliris for the treatment of patients with PNH. Soliris is the first drug therapy ever approved under Priority Review in the U.S. and through the Accelerated Assessment procedure in Europe.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their pres
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
2. Kuvan Receives Positive Opinion From CHMP for European Approval
3. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
4. Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets
5. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
6. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
7. PLC Systems Receives Delisting Notice From American Stock Exchange
8. Nephros Receives Non-Compliance Notification from AMEX
9. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
10. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
11. Intact Medical Corporations Intact(R) Excise XL Receives 510(K) Marketing Clearance from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... SAN DIEGO , Dec. 22, 2014 ... that the Decipher Prostate Cancer Classifier, a genomic test ... disease in node-negative, high-risk men managed by radical prostatectomy ... with radical prostatectomy is relatively uncommon, using tumor genomics ... form of metastatic disease is an important advance. The ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Wis. The planned Wisconsin Institute for Discovery has ... Wisconsin-Madison: $50 million from John and Tashia Morgridge. , ,The ... Research Foundation, and the State Building Commission has approved $50 ... , ,John Morgridge, chairman of the board of Cisco Systems ...
... case anyone doubts that the Wisconsin Alumni Research Foundation has ... cell patent, Andy Cohn would like to disabuse them of ... said the foundation, armed with a $1.5 billion endowment, is ... stem cell patent. , ,In the wake of recent events, ...
... many companies have been downsizing their domain name portfolios ... had cooled. There has not been, however, a corresponding ... increase in the number of domain name cases filed ... name market has been reinvigorated due to the development ...
Cached Biology Technology:Morgridge gift enables phase one of Institute for Discovery 2WARF says it's ready for a legal challenge on stem cells 2WARF says it's ready for a legal challenge on stem cells 3WARF says it's ready for a legal challenge on stem cells 4Renew your domain name! 2Renew your domain name! 3Renew your domain name! 4
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... (PHILADELPHIA) An international team of researchers ... of Penn Medicine,s Institute for Translational Medicine and ... the Paris-based Fondation Leducq to study the molecular ... "Molecular Mechanisms of Novel Genes Associated with Plasma ...
... equity fund that specializes in making concentrated investments ... is co-managed by Philip Sassower, CEO, and Andrea ... Chairman and CEO, while Mr. Goren is the ... StatementsCertain statements contained in this press release, including ...
... A multidisciplinary clinical practice guideline, "Tonsillectomy in Children" ... OtolaryngologyHead and Neck Surgery (watch for a new ... The new guideline provides evidence-based recommendations on the pre-, ... 1 to 18 years under consideration for tonsillectomy. Additionally, ...
Cached Biology News:Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Tonsillectomy in children 2
...
... AgarACE Enzyme(a) is a unique agarose-digesting enzyme ... recovery of intact DNA or RNA from ... that low melting point (LMP) agarose melted ... equilibrated to the reaction temperature before hydrolysis. ...
... (TdT) is an intracellular marker normally present ... minor subpopulation of bone marrow prelymphocytes. Elevated ... of TdT cells are found to be ... Presence of TdT thus provides a useful ...
Request Info...
Biology Products: